Title |
Perspectives on epigenetic-based immune intervention for rheumatic diseases
|
---|---|
Published in |
Arthritis Research & Therapy, March 2013
|
DOI | 10.1186/ar4167 |
Pubmed ID | |
Authors |
Steven G Gray |
Abstract |
Rheumatic disease can loosely be described as any painful condition affecting the loco-motor system, including joints, muscles, connective tissues, and soft tissues around the joints and bones. There is a wide spectrum of rheumatic diseases, many of which involve autoimmunity, including systemic lupus erythematosus and rheumatoid arthritis. A significant body of evidence now links aberrant epigenetic regulation of gene expression with rheumatic disease and points toward the use of epigenetic targeting agents as potential new treatment options, particularly for those conditions associated with an autoimmune element. In this perspective, I will briefly cover the current knowledge surrounding this area in the field of rheumatology. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 67% |
United Kingdom | 1 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Science communicators (journalists, bloggers, editors) | 1 | 33% |
Members of the public | 1 | 33% |
Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 4% |
Turkey | 1 | 4% |
Canada | 1 | 4% |
Unknown | 24 | 89% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 7 | 26% |
Researcher | 5 | 19% |
Student > Master | 4 | 15% |
Student > Postgraduate | 3 | 11% |
Student > Bachelor | 1 | 4% |
Other | 2 | 7% |
Unknown | 5 | 19% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 8 | 30% |
Agricultural and Biological Sciences | 6 | 22% |
Biochemistry, Genetics and Molecular Biology | 5 | 19% |
Immunology and Microbiology | 1 | 4% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
Other | 0 | 0% |
Unknown | 6 | 22% |